Drug-device combination products under MDR Article 117

Introduced by the European Commission under the Medical Devices Regulation (MDR), Article 117 requires manufacturers placing drug-device combination products onto the market as an integral device and marketing them as a “medicinal product” to seek a Notified Body Opinion (NBOp). The notified body then confirms whether the device is compliant with the relevant General Safety and Performance Requirements (GSPR) and provides an NBOp Report to the manufacturer to include the Market Authorisation Application (MAA).

Visit our drug-device combination products webpage for more information on seeking an NBOp from BSI. 




Stay up to date with the latest updates from BSI